Cancer Bio-Immunotherapy

xiv NIBIT

13-15 October 2016

Meeting in Siena

BANCA MONTE DEI PASCHI DI SIENA
Rocca Salimbeni – Piazza Salimbeni 1

SCIENTIFIC PROGRAM
SESSION 1. Cancer genetics and immunotherapy

Chairs: Mario Paolo Colombo (Milan, Italy), Paola Nisticò (Rome, Italy)

14:00 Giuseppe Palmieri (Sassari, Italy)
Genomic profiles and response to immunotherapy

14:25 Gennaro Ciliberto (Naples, Italy)
A complex network of miRNAs is responsible for the establishment of resistance to targeted therapy in metastatic melanoma

14:50 Zlatko Trajanoski (Innsbruck, Austria)
Immunophenotypes and antigenomes of solid cancers

Selected Abstract

15:15 Luigi Buonaguro (Naples, Italy)
Discovery to first-in-man studies of a multipeptide-based hepatocellular carcinoma vaccine adjuvant with CV8102 - HEPAVAC

Chair: F. Cavallo

15:30 Keynote lecture
Alberto Mantovani (Milan, Italy)
Tumor-associated macrophages in tumor progression: from bench to bedside

16:00 Coffee break

SESSION 2. Tumor microenvironment

Chairs: Maria Pia Protti (Milan, Italy), Vincenzo Russo (Milan, Italy)

16:15 Hermann-Wolf Fridman (Paris, France)
Clinical impact of immune microenvironments in different types of human cancer

16:40 Barbara Seliger (Halle, Germany)
Immunomodulatory microRNAs as a novel mechanism to revert immune escape of tumors

17:05 Claudio Tripodo (Palermo, Italy)
Overriding the inflammatory microenvironment

Invited Abstracts

17:30 Antonio Sica (Milan, Italy)
NAMPT: a metabolic link with tumor-related immunosuppression

Chair: Mario Mandalà (Bergamo, Italy)
beta-catenin IHC overexpression and lack of CD8+ T-cells predict resistance and poor prognosis in metastatic melanoma patients receiving MAPKi

17:45 Special event
A big piece of history in Italian Immuno-Oncology: a multivoice interview.
Soldano Ferrone (Boston, USA), Pier Giorgio Natali (Rome, Italy), Giorgio Parmiani (Milan, Italy), Umberto Tirelli (Aviano, Italy)

Ensemble Director
Alberto Amadori (Padua, Italy)

19:00 NIBIT General Assembly

20:00 Dinner
SESSION 3. Mesothelioma workshop

**Chairs:** Marco Bregni (Milan, Italy), Massimo Di Nicola (Milan, Italy)

8:30  **Giovanni Luca Ceresoli** *(Bergamo, Italy)*
Current treatments

8:55  **Luana Calabrò** *(Siena, Italy)*
The NIBIT MESO-1 trial

9:20  **Joachim Aerts** *(Amsterdam, NL)*
Future perspectives

**Selected Abstract**
9:45  **Carla Chiarucci** *(Siena, Italy)*
Novel immune-related molecules in the serum of malignant mesothelioma patients treated with tremelimumab

10:00  **Coffee break**

SESSION 4. Immune checkpoints

**Chairs:** Michele Maio (Siena, Italy), Matteo Bellone (Milan, Italy)

10:30  **Sergio Quezada** *(London, UK)*
Clonal neoantigens elicit T-cell immunoreactivity and sensitivity to immune checkpoint blockade

10:55  **Giorgio Scagliotti** *(Turin, Italy)*
Immunotherapy of lung cancer

11:20  **Stephen J. O’Day** *(Santa Monica, USA)*
Immunotherapy of melanoma and other solid tumors

11:45  **Carmelo Carlo-Stella** *(Milan, Italy)*
Immunotherapy of hematologic malignancies

**Selected Abstracts**
12:10  **Angela Elia Rita** *(Milan, Italy)*
Improving efficacy of adoptive T-cell therapy against cancer by combining targeted cytokines and inhibitory checkpoints blockers

12:25  **Massimiliano Pagani** *(Milan, Italy)*
Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating regulatory T-cells

12:40  **Lunch**
### SESSION 5. How immunotherapy shapes company pipelines

**Chairs:** Roberto Camerini (Bologna, Italy), Olivier Provendier (Paris, France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Company</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Cosimo Paga (BMS)</td>
<td>Immuno-Oncology at BMS</td>
<td></td>
</tr>
<tr>
<td>13:55</td>
<td>Zhen Su (Merck)</td>
<td>Immuno-Oncology at Merck</td>
<td></td>
</tr>
<tr>
<td>14:20</td>
<td>William Grossmann (Roche)</td>
<td>Immuno-Oncology at Roche</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>Aiman Shalabi (AstraZeneca)</td>
<td>Immuno-Oncology at AstraZeneca</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>Michael Lahn (Incyte)</td>
<td>Immuno-Oncology at Incyte</td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td>Claudio Bordignon (MolMed)</td>
<td>Immuno-Oncology at MolMed</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Pietro Taverna (Astex)</td>
<td>Immuno-Oncology at Astex</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Philippe Legenne (Amgen)</td>
<td>Immuno-Oncology at Amgen</td>
<td></td>
</tr>
<tr>
<td>16:50</td>
<td>Ramy Ibrahim (Parker Institute for Cancer Immunotherapy)</td>
<td>I-O programs Immuno-Oncology at Parker Institute</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>Keynote Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Soldano Ferrone (Boston, USA)</td>
<td>“HL antigens: a forgotten issue”</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>Social dinner</td>
<td>Chiostro di San Francesco</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 5. How immunotherapy shapes company pipelines

Chairs: Roberto Camerini (Bologna, Italy), Olivier Provendier (Paris, France)

13:30 Cosimo Paga (BMS) Immuno-Oncology at BMS
13.55 Zhen Su (Merck) Immuno-Oncology at Merck
14:20 William Grossmann (Roche) Immuno-Oncology at Roche
14:45 Aiman Shalabi (AstraZeneca) Immuno-Oncology at AstraZeneca
15:10 Michael Lahn (Incyte) Immuno-Oncology at Incyte
15:35 Claudio Bordignon (MolMed) Immuno-Oncology at MolMed
16:00 Pietro Taverna (Astex) Immuno-Oncology at Astex
16:25 Philippe Legenne (Amgen) Immuno-Oncology at Amgen
16:50 Ramy Ibrahim (Parker Institute for Cancer Immunotherapy) I-O programs Immuno-Oncology at Parker Institute
17:15 Coffee break

SESSION 6. Cell and gene therapy of cancer

Chairs: Anna Mondino (Milan, Italy), Pier Francesco Ferrucci (Milan, Italy)

8:30 Antonio Rosato (Padua, Italy) Tumor antigen-specific retargeting of CIK cell adoptive therapy
8:55 Andrea Velardi (Perugia, Italy) Alloreactive NK cells for haploidentical hematopoietic stem cell transplantation
9:20 Fabio Ciceri (Milan, Italy) Adoptive T-cell therapy with HSV-TK-engineered T lymphocytes
9:45 Giulia Casorati (Milan, Italy) Targeting leukemia with lipid specific T-cells
10:10 John Hiscott (Rome, Italy) Combination strategies to augment oncolytic immunotherapy of cancer
10:35 Lena Kranz (Mainz, Germany) Systemic mRNA-encoded antigen delivery to lymphoid-resident DCs sets the stage for a potent antitumor immunity
10:50 Marinos Kallikourdis (Milan, Italy) Tailored chemokine receptor modifications improves homing of adoptive therapy cells in a spontaneous tumor model and leads to identification of conflicting roles that T-cells may play in a therapeutic complex
11:05 Coffee break
11:20 Guest Lecture
Introduction: Michele Maio (Siena, Italy) Roberto Bernabei (Rome, Italy) Immunotherapy in elderly patients

SESSION 7. Ongoing and prospective NIBIT activities and collaborations

Chairs: Enrico Proietti (Rome, Italy), Paola Zanovello (Padua, Italy)

11:50 Anna Maria Di Giacomo (Siena, Italy) The NIBIT future prospects
12:05 Pier Franco Conte (Padua, Italy) The A-BRAVE trial
12:20 Andrea Anichini (Milan, Italy) Mechanisms of response and resistance to immune checkpoint blockade in melanoma: analysis at tumor site
12:25 Special Event Graham Pawelec (Tubingen, Germany) Meet-the-Editor
13:05 NIBIT AWARDS
13:30 Lunch
14:30 Adjourn
NIBIT A STEP AHEAD TOGETHER
<table>
<thead>
<tr>
<th>SPONSOR (OTHER SUPPORTERS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Incyte</td>
</tr>
<tr>
<td>MSD Oncology</td>
</tr>
<tr>
<td>Roche</td>
</tr>
<tr>
<td>Azienda Ospedaliera Universitaria Senese</td>
</tr>
<tr>
<td>astex pharmaceuticals</td>
</tr>
<tr>
<td>AMGEN</td>
</tr>
<tr>
<td>AstraZeneca</td>
</tr>
<tr>
<td>MERCK Serono</td>
</tr>
<tr>
<td>Fondazione NIBIT</td>
</tr>
</tbody>
</table>
Cancer Bio-Immunotherapy

xIV NIBIT

Thanks to Banca Monte dei Paschi di Siena for hosting the international NIBIT Meeting in its historical headquarters.